Case Report: First report of Elizabethkingia miricola infection in a patient with cystic fibrosis. by Frost, Freddy & Nazareth, Dilip
 Open Peer Review
Discuss this article
 (0)Comments
CASE REPORT
Case Report: First report of infection inElizabethkingia miricola 
 a patient with cystic fibrosis
Freddy Frost , Dilip Nazareth
Liverpool Heart & Chest Hospital, Liverpool, L14 3PE, UK
Abstract
 is a rare non-fermenting Gram-negative rod that hasElizabethkingia miricola
previously been reported to be associated with blood stream and pulmonary
abscess infections, but never before in cystic fibrosis (CF). Here we present the
first reported case of  infection in a patient with CF andElizabethkingia miricola 
discuss the management options. We describe a patient with CF in whom we
observed clinical and spirometric evidence of pulmonary exacerbation with the
associated growth of  in sputum culture. The period of clinicalE. miricola 
instability was observed to coincide with the obtainment of four sputum
samples from which  was cultured; improvement was seen followingE. miricola 
treatment with ciprofloxacin and the subsequent eradication of  . WeE. miricola
conclude that   is able to survive in the CF lung and in this case wasE. miricola
associated with pulmonary exacerbation. Empirical treatment with
fluoroquinolones is appropriate, based on our experience.
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Introduction
Elizabethkingia miricola, a non-fermenting Gram-negative 
rod (NFGNB) was first identified following isolation from 
condensation water in the Russian space laboratory Mir1. 
Originally identified as belonging to the Chryseobacterium 
genus, it has since been re-classified and is closely related to 
Elizabethkingia. meningoseptica (previously C. meningosep-
ticum). E. miricola has been demonstrated to be pathogenic, 
with reports of bacteraemia resulting in sepsis and pulmonary 
abscesses2,3. Here, we report the presence of E. miricola in the 
sputum of a patient with cystic fibrosis (CF). To our knowledge, 
this is the first reported case of E. miricola infection in CF; 
herein, we discuss the case itself and the literature surrounding 
this bacterium to help guide clinicians faced with similar clinical 
scenarios.
Case report
A 49-year-old male with a diagnosis of CF presented to his 
routine CF outpatient department complaining of feeling 
generally unwell. He reported increased cough, but this was 
non-productive. There was a drop in lung function, from a 
baseline forced expiratory volume in one second (FEV1) of 
2.39 l (65% of the predicted volume) to 2.19 l (60% predicted). A 
sputum sample was taken and sent for routine culture, but given 
the non-specific symptoms and mild drop in FEV1, it was agreed 
that no immediate treatment was required and a follow-up in 
4 weeks’ time was arranged.
Co-morbidities of the patient included osteoporosis and 
pancreatic insufficiency; he was also receiving treatment for 
allergic bronchopulmonary aspergillosis (ABPA). Cultured res-
piratory samples in the previous year had consistently grown 
non-epidemic Pseudomonas aeruginosa. The diagnosis of CF 
was made in adulthood and was based the presence of bilateral 
bronchiectasis on a chest CT scan, a raised chloride level 
following a skin sweat test and genetic testing, which revealed 
that the patient was heterozygous for the CFTR F508del mutation. 
Family history included a younger sister who had died aged 
23 years from pancreatitis.
A sputum sample taken at the clinic appointment was positive for 
P. aeruginosa, and extended incubation isolated Elizabethkingia 
miricola. At the next appointment, worsening symptoms were 
observed, including increasing shortness of breath, wheeze and 
productive cough. There was a further drop in FEV1 to 1.91 L 
(52% predicted) (Figure 1). On the basis of outcomes of 
previous infective exacerbations, an oral course of chloram-
phenicol (500 mg four times a day) along with prednisolone 
(30 mg daily) for 2 weeks was commenced and a further 
sputum sample was obtained. Sputum culture was again positive 
for P. aeruginosa and E. miricola.
A further 4 weeks later, symptoms were somewhat improved 
and FEV1 lung function had increased to 2.19 l (60% predicted). 
However, another 2 weeks later, symptoms deteriorated again, 
with an associated decline in lung function (FEV1, 1.95 l; 53% 
predicted). Sputum cultures from the previous admission were 
again positive for P. aeruginosa and E. miricola. Sensitivities 
from previous samples revealed E. miricola resistant to 
meropenem and ceftazidime, but sensitive to piperacillin/ 
tazobactam and ciprofloxacin (CIP). A 2-week course of oral 
CIP (750 mg thrice daily) was therefore commenced.
The patient noted an improvement in symptoms and at the 
next clinic appointment FEV1 had improved to 2.08 l (57% pre-
dicted). Sputum then grew P. aeruginosa and yeast only. A 
further four subsequent sputum samples 1, 4, 8 and 12 months 
later have grown P. aeruginosa but no E. miricola, and lung 
function returned towards baseline.
Figure 1. Lung function before and after positive sputum culture for Elizabethkingia miricola. Lung function wsa measured using 
forced expiratory volume in one second (FEV1). Dotted lines represent the time period between which four sputum cultures were positive for 
E. miricola.
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Discussion
E. miricola has been described in a number of healthcare 
settings, but not previously in CF. One of the first reports of 
E. miricola infection was of positive growth in blood and 
sputum cultures of a septic patient whom had recently undergone 
a stem-cell transplant for mantle-cell lymphoma. Since then it has 
been reported in only a handful of cases, including septicaemia 
in a young patient with alcoholic pancreatitis and in the sputum 
of a septic patient with pulmonary abscesses2,3. More recently, 
E. miricola was identified as causing a UTI in an immunocompe-
tent adult4.
Here, we describe a patient with CF in whom we observed 
clinical and spirometric evidence of pulmonary exacerbation, 
with associated growth of E. miricola in sputum culture. The 
period of clinical instability was observed to coincide with four 
sputum samples culturing E. miricola and improvement was 
seen with treatment. This is the first report of E. miricola in an 
individual with CF, meaning this report should therefore be 
relevant to all CF clinicians and microbiologists involved in the 
care of people with CF.
All case reports of E. miricola infection mentioned above report 
identification by MALDI-TOF (matrix-assisted laser desorp-
tion/ionisation time-of-flight) mass spectrometry2–4. MALDI-
TOF has been widely adopted for bacterial identification, 
facilitating diagnosis quickly and reliably. In the CF setting, 
MALDI-TOF has also been shown to be particularly useful in 
identifying non-fermenting gram-negative bacteria, for which 
classification can be difficult using conventional phenotypic 
approaches5. Given the increasing use of MALDI-TOF in 
clinical microbiology laboratories, identification of NFGNB 
infections is likely to rise. Hence, establishing the optimal initial 
management strategies for these infections is important.
In this case, initial empirical treatment with oral chlorampheni-
col did not clear the infection, but treatment with oral CIP (based 
on culture sensitivities) successfully treated the exacerbation. 
Eradication of E. miricola was also observed, with contem-
poraneous clinical improvement. Notably, the sputum culture 
sensitivities revealed that P. aeruginosa was resistant to CIP, 
further supporting the idea that E. miricola had a pathogenic role. 
Our experience of treatment with a fluoroquinolone is in keeping 
with that of previous reports, in which E. miricola bacteraemia 
has been associated with sensitivity to levofloxacin and/or CIP, 
both of which resulted in successful treatment2,6,7. Suscepti-
bility to co-trimoxazole (SXT) has also been reported, and it 
would seem that treatment with fluoroquinolones or SXT is an 
appropriate empirical strategy.
Conclusion
E. miricola appears to have the potential to grow in the CF lung 
and can be associated with pulmonary exacerbation. Given the 
paucity of information on E. miricola infection in CF, we hope 
that the case report and literature review herein are relevant to CF 
clinicians and microbiologists alike. Treatment based on 
culture sensitivity is recommended, but empirical treatment with 
fluoroquinolones may be an appropriate initial strategy if there is 
suspicion of pathogenicity.
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